Tekmira Presents Recent Advances in mRNA Delivery at Scientific Symposium
February 25, 2014 02:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA therapeutics, announced that recent advances in...
Tekmira Announces Filing of Shelf Prospectus and Registration Statement
February 21, 2014 14:54 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a developer of RNA interference (RNAi) therapeutics, today announced that it...
Webcast Advisory: Tekmira to Present at the 2014 RBC Capital Markets' Global Healthcare Conference
February 20, 2014 17:09 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Announces New Appointment to Board of Directors
February 12, 2014 15:45 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced the...
Tekmira to Present at the 16th Annual BIO CEO & Investor Conference
February 05, 2014 14:45 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr....
Tekmira Receives US$14.5 Million Milestone Payment
January 21, 2014 07:15 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, confirmed today...
Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola
January 14, 2014 13:51 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Signs Development Agreement on Delivery Technology for Agricultural Applications
January 13, 2014 07:15 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Announces Strategic Reorganization to Strengthen Leadership Team
January 06, 2014 16:00 ET
|
Arbutus Biopharma Corporation
Dr. Michael Abrams Appointed Chief Discovery Officer
Dr. Ian MacLachlan Named Chief Technical Officer
VANCOUVER, British Columbia, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals...
Tekmira Receives $5 Million Milestone Payment for Phase III Initiation of LNP-Enabled Patisiran (ALN-TTR02)
December 16, 2013 19:50 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...